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Type 1 diabetes (T1D) is a chronic autoimmune disease that results from destruction
of pancreatic β-cells. T1D subjects were recently shown to harbor distinct intestinal
microbiome profiles. Based on these findings, the role of gut bacteria in T1D is being
intensively investigated. The mechanism connecting intestinal microbial homeostasis
with the development of T1D is unknown. Specific gut bacteria such as Bacteroides
dorei (BD) and Ruminococcus gnavus (RG) show markedly increased abundance prior
to the development of autoimmunity. One hypothesis is that these bacteria might traverse
the damaged gut barrier, and their constituents elicit a response from human islets
that causes metabolic abnormalities and inflammation. We have tested this hypothesis
by exposing human islets to BD and RG in vitro, after which RNA-Seq analysis
was performed. The bacteria altered expression of many islet genes. The commonly
upregulated genes by these bacteria were cytokines, chemokines and enzymes,
suggesting a significant effect of gut bacteria on islet antimicrobial and biosynthetic
pathways. Additionally, each bacteria displayed a unique set of differentially expressed
genes (DEGs). Ingenuity pathway analysis of DEGs revealed that top activated pathways
and diseases included TREM1 signaling and inflammatory response, illustrating the ability
of bacteria to induce islet inflammation. The increased levels of selected factors were
confirmed using immunoblotting and ELISA methods. Our data demonstrate that islets
produce a complex anti-bacterial response. The response includes both symbiotic and
pathogenic aspects. Both oxidative damage and leukocyte recruitment factors were
prominent, which could induce beta cell damage and subsequent autoimmunity.
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HIGHLIGHTS
- Gut dysbiosis and impaired gut permeability are features of type 1 diabetes (T1D).
- Bacteroides dorei (BD), Ruminococcus gnavus (RG) are two bacteria increased at time of onset
of T1D.
- Exposure of isolated human islets to BD or RG revealed bacteria-specific alterations in gene
expression profiles.
- The genes upregulated by both BD and RG were dominated by cytokines and chemokines
suggesting an islet antibacterial response involving subsequent recruitment of immune cells.
Abdellatif et al. Human Islets Antibacterial Response
- Findings of our study uncovered key features of the islet
response toward invading bacteria.
INTRODUCTION
Type 1 diabetes (T1D) is a life-threatening disease with a rapidly
increasing incidence in children and adolescents (1). T1D is
thought to result from the destruction of insulin producing
pancreatic β-cells by self-reactive T cells that infiltrate the islets
(2). However, its etiology remains poorly understood. The genetic
susceptibility to T1D is associated with specific human leukocytes
antigen (HLA) alleles (3), though<10% of genetically susceptible
people develop clinical T1D (4). This variation demonstrates that
non-genetic factors, e.g., those contributed by the environment,
could play an important role in pathogenesis of the disease (5).
The gastrointestinal tract (GIT) represents the largest
compartment in the body where the host experiences the
external environment (6). Intestinal biopsies from children
with T1D revealed distinctive inflammatory changes (7).
Moreover, increased expression of inflammatory cytokines in the
duodenal mucosa of T1D patients was associated with altered
composition of the gut microbiome (dysbiosis) (8). In this regard,
several recent studies have also reported intestinal dysbiosis
in individuals with newly diagnosed T1D (9–13). Differential
abundance of certain microbial communities e.g., increased
Bacteroides and decreased short chain fatty acids (SCFA)-
producing bacteria, was reported as a common feature in T1D by
the aforementioned studies. Bacteroides dorei and Ruminococcus
gnavus are two bacterial species noted to be increased in
infants genetically susceptible to T1D at/before development of
autoantibodies (14, 15). An increased intestinal permeability was
also reported in children at risk for T1D (16). The disruption
of the gut epithelial barrier and subsequent leakage of microbial
products into pancreas could be a predisposing factor to T1D,
as suggested by Korsgren et al. (17). Indeed, whether bacterial
products can elicit a response within the pancreas remains largely
unknown. Costa et al. (18) noted translocation of gut bacteria to
pancreatic lymph nodes (PLNs) of streptozotocin (STZ)-injected
mice, an experimental model of T1D, by both morphological
and molecular approaches. Such translocation was thought to
contribute to the pathogenesis of T1D by activating pathogenic
T helper 1 (Th1) and Th17 cells that expanded in the PLNs
and pancreas. Despite the many advances in our knowledge of
changes in the gut microbiome during T1D progression, their
role in pathogenesis remains unknown. The intrinsic response
of human islets to specific bacteria, especially those of the gut in
T1D subjects remains unknown.
In the present study, we experimentally tested the hypothesis
that intestinal dysbiosis and leakage of bacteria into the human
pancreas could trigger an anti-bacterial immune response
from islets. To achieve that aim, isolated human islets were
exposed to Bacteroides dorei or Ruminococcus gnavus, two
bacteria overrepresented in the gut just before/at incidence
of autoimmunity in T1D susceptible individuals (14, 15)
and Escherichia coli, a ubiquitous bacterium associated with
accelerated maturation of the gut microbiome (19, 20) for 6
or 24 h. Islets exposed to the potent cytokine IL-1β for the
same time periods were used as positive controls. To gain
insights into the mechanisms associated with the islet specific
antibacterial response, next generation sequencing (NGS) was
performed. Differentially expressed genes (DEGs) were subjected
to core analysis using Ingenuity Pathway Analysis (IPA) software.
IPA analysis revealed distinct sets of transcripts, canonical
pathways, upstream regulators, diseases, and networks specific
to each bacterium. The list of DEGs common to all bacteria
and IL-1β at both 6 and 24 h are dominated by cytokines,
chemokines, and enzymes. Our results identify unique bacteria-
specific transcriptional changes revealing both protective and
pathogenic features of the islet bactericidal response.
MATERIALS AND METHODS
Bacterial Culture and Preparation of
Inocula
Bacteroides dorei (BD, Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures Cat#
17855), Escherichia coli (EC, Invitrogen Cat# 18258012),
and Ruminococcus gnavus (RG, ATCC, Cat# 29149) were
purchased from commercial vendors and grown according to
standard protocols. Both BD and RG were grown anaerobically
in tryptic soy broth supplemented with Oxyrase (Oxyrase
Inc.) and resazurin salt (Sigma-Aldrich) while EC was grown
aerobically in Luria-Bertani broth. All bacteria were allowed
to reach early/mid-stationary phase of growth. At the end of
culture, bacteria were fixed in 4% paraformaldehyde (PFA) for
30min, rinsed three times with sterile PBS and then reconstituted
in sterile physiological saline. To ensure all bacteria were killed,
bacterial stocks were used to inoculate additional broth. Absence
of bacterial growth 48 h after inoculation under standard
culturing conditions indicated all bacteria were killed by the
PFA exposure. For confirmation of the purity of tested bacteria,
genomic sequencing was performed for each bacterial strain
(Supplementary Table 1).
Study Subjects
Primary human cadaveric islets from eight non-diabetic
donors (21–58 years old) were ethically obtained from
Prodo Laboratories Inc (Aliso Viejo, CA, USA). The donor
characteristics are provided in Supplementary Table 2.
Culture and Viability Assessment of Islets
Upon arrival, islets were initially incubated for 6–24 h at 37◦C
in CMRL-1066 medium (Gibco, USA) supplemented with 2mM
l-glutamine, 1% penicillin-streptomycin, and 10% fetal bovine
serum (FBS). After that, individual donor islets were cultured in
4-well plates containing FBS-free media at 1,000 islet equivalents
(IEQs) per well. Each well was exposed to one of the three
bacterial strains at 10 bacteria per cell (BpC) for 6 or 24 h. Time
matched controls were also included using IL-1β (InvivoGen) at
1 ng/ml (positive control) and FBS-free media (negative control).
Bacteria and IL-1β concentrations were considered appropriate if
they induced significant changes in the percent of viable IEQs in
a given treatment within 24 h. In order to monitor the viability
of IEQs throughout different incubations, a dithizone (DTZ)
assay was performed according to the standard protocol from
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FIGURE 1 | Optimized bacterial and IL-1β exposures induced significant and
comparable reductions in human islet viability. (A) Aggregate viable IEQs
across all treatment conditions significantly decreased (∼20%) from the initial
(0 h) to the experimental end points. (B) No significant differences in viable IEQs
were observed in serum free controls (SFC) or between individual bacteria (BD,
B. dorei; EC, E. coli; RG, R. gnavus) exposure groups while bacteria-exposed
islets displayed reduced viabilities relative to SFC at 24 h, indicating significant,
but comparable reductions in viability across bacteria. Data are shown as
averages ± standard error of the mean. *P < 0.05. Ns, not significant.
the National Institutes of Health (NIH) at the beginning and end
of each experiment (21). Islet viability was 90.2 ± 2.4% at the
onset of the exposure period and declined, on average, <20%
throughout the treatment period (Figure 1A). While there was
no significant difference between the experimental conditions
(Figure 1B), the percentage of viable IEQs significantly decreased
from the zero point to 6 h and from the 6 to 24 h. This limited, yet
significant, reduction in islet viability was essential for detecting
the changes in transcript levels in the remaining islets. At the
end of exposure, ∼500 IEQs from each condition were prepared
for RNA isolation while ∼300 IEQs were prepared for protein
extraction and subsequent western blot analysis. Supernatants
were additionally collected from each sample. All samples were
subsequently flash frozen on dry ice and stored at −80◦C until
further use.
RNA Sequencing
A total of 42 samples [serum-free control (SFC), IL-1β-
6 h, and EC-6 h = 6 each and IL-1β-24 h, EC-24 h, BD-
6 h, BD-24 h, RG-6 h & RG-24 = 4 each] derived from six
human islet donors exposed to various treatment conditions
were analyzed using NGS. Briefly, total RNA was isolated
using Qiagen RNeasy Minikits (Qiagen) according to the
manufacturer’s recommendations. Next, RNA integrity and
concentration were assessed using an Agilent Bioanalyzer 2100
(Agilent) and Nanodrop Spectrophotometer, respectively. After
that, cDNA libraries were generated using a SciClone NGS
Library Production Robot (Perkin Elmer) and library quality was
verified using the Agilent Bioanalyzer. RNA sequencing (RNA-
Seq) was subsequently performed using an Illumina HiSeq2500
system (Illumina, San Diego, CA, USA) to achieve single 100
base pair reads with a read depths of 15–20 million reads per
sample. Short raw sequence reads were downloaded from the
HiSeq2500 server in FASTQ format and individually mapped
to the human reference genome (hg38) using TopHat. The
complete bioinformatics analysis pipeline for the RNAseq data
was performed using the Tuxedo protocol, which includes
TopHat, Cufflinks, Cuffmerge, and Cuffdiff (22). Differential
gene expression analysis results from the Cufflinks analysis of
individual samples were reported as Fragments Per Kilobase of
transcript per Million Mapped reads (FPKM) which reports the
normalized expression values for a given gene and accounts for
multiple reads for an individual fragment. Transcripts up- and
downregulated relative to controls were considered significantly
changed only when the false discovery rate (FDR) adjusted p-
value (q-value) was<0.05. Relative differences in gene expression
were assessed by comparing the log2-fold change values between
the islet FPKMs for bacteria-treated and time-matched controls.
For easier interpretation of obtained datasets, all log2-fold change
values were converted to their equivalent numeric values. Fastq
files and RNA-Seq processed data were deposited into the NCBI
GEO repository under the accession number GSE131320.
Ingenuity Pathway Analysis and Data
Visualization
The obtained datasets of DEGs were filtered using cut-offs of
± 2 and 0.05 for fold change and q-value, respectively. The
generated lists of DEGs from all treatments were uploaded into
the IPA software (Ingenuity Systems, Redwood City, CA) for
core analyses. Initially, each group was analyzed separately using
default parameters for altered canonical pathways, upstream
regulators, diseases, and networks. After that, all groups were
compared with each other to elucidate both shared and unique
features induced by each treatment. Z-score is a statistical
measure of the match between expected relationship direction
and observed gene expression (23). Changes with an activation z-
score≥2 or≤−2 were considered significant. To show canonical
pathways with highest significant changes, the list of differentially
expressed pathways were further trimmed at p-value≤0.05 in the
IPA software. Venn diagrams of shared and unique DEGs were
done using an online tool from Bioinformatics & Evolutionary
Genomics (24). Heat maps of DEGs common to all groups at 6
and 24 h were generated using ClustVis (25).
Protein Extraction and Immunoblotting
Following culture, pancreatic islets were immediately rinsed
with ice-cold PBS followed by lysis with Mammalian-Protein
Extraction Reagent (M-PER, Pierce Biotechnology, MA, USA)
supplemented with Halt Protease and Phosphatase Inhibitor
cocktail (Thermo Scientific). The concentrations of the extracted
proteins were then determined with Bio-Rad total protein assay
(Bio-Rad, USA). Protein lysates were diluted in 4X Laemmli
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FIGURE 2 | Differentially expressed genes (DEGs) at 6 and 24 h by all groups. (A,E) Number of DEGs in human islets after individual bacteria or IL-1β exposure for 6
or 24 h, respectively. (B,C) Venn diagrams indicating the overlap of up- (B) and down-regulated (C) genes at 6 h in all groups. (D) Heatmap of the hierarchical
clustering of the shared DEGs at 6 h depicting their expression patterns. (F,G) Venn diagrams indicating the overlap of up- (F) and down-regulated (G) genes at 24 h in
all groups. (H) Heatmap of the hierarchical clustering of the shared DEGs at 24 h depicting their expression patterns. Genes were clustered based on log2 of their
expression values using Pearson’s correlation and complete linkage function. The color key indicates the direction of changes: red and blue depict significant up- and
down-regulation, respectively.
buffer, heated at 95◦C for 5min, and two micrograms of the
extracted proteins were loaded per each lane onto a 4–15%
precast polyacrylamide gel (Bio-Rad, USA) for electrophoresis
and electro-transferred to polyvinylidene difluoride (PVDF)
membranes (Thermo Scientific). The membranes were then
blocked in 5% non-fat dry milk in TBS-0.1% Tween-20 (TBST)
for 2 h at room temperature. Blocked membranes were then
incubated overnight at 4◦C with primary antibodies against
NAMPT (dilution 1:2,000, P4D5AT, Enzo Life Sciences Inc., NY,
USA), TRAF3IP2 (1:200, sc-100647, Santa Cruz Biotechnology
Inc., CA, USA), SOD2 (1:10,000, #13141, Cell Signaling
Technology MA, USA), and GAPDH (1:10,000, sc-365062, Santa
Cruz Biotechnology). The next day the membranes were washed
three times in TBST and incubated for 1 h at room temperature
with corresponding peroxidase-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories, PA, USA) at dilution
rates of 1:40,000 for NAMPT and 1:80,000 for others. Bound
antibodies were visualized using ECL (SuperSignal West Femto
Maximum Sensitivity Substrate or SuperSignal West Pico PLUS
Chemiluminescent Substrate (Pierce Biotechnology) depending
on the expected signal strength) and recorded on X-ray
films. Immunoblots were stripped and reprobed with GAPDH
antibody, served as loading control, and the relative band
intensities were measured using the ImageJ software 1.46r
(National Institutes of Health; http://imagej.nih.gov/ij/).
Enzyme Linked Immunosorbent Assay
Sandwich ELISA kits from R&D Systems (R&D Systems Inc.,
Minneapolis, USA) for IL-8 (Cat# DY208-05), CXCL1 (Cat#
DY275-05), CCL20 (Cat# DM3A00), and CXCL6 (Cat# DGC00)
were used for measuring their concentrations in islet culture
supernatants per manufacturer instructions. All samples were
assayed in duplicate.
Statistical Analysis
Graphs for western blot and ELISA were drawn using GraphPad
Prism 7 (GraphPad Software, CA, USA). The differences between
groups were determined using the ANOVA test. Post-hoc t-
tests were run to evaluate group-specific differences when
warranted by a significant ANOVA. P-values ≤0.05 were
considered significant.
RESULTS
Bacteria and IL-1β Induce Differential Gene
Expression in Isolated Human Islets
Gene expression profiling of human islets incubated with BD, EC,
RG, or IL-1β revealed alterations in gene expression levels at both
6 and 24 h (Figure 2, Supplementary Table 3). Among the three
tested bacteria, EC was associated with the highest number of
DEGs at 6 and 24 h (459, 310), followed by RG (305, 225), and BD
(157, 151). IL-1β treatment altered the expression of 923 and 783
genes at 6 and 24 h, respectively. These DEGs were dominated
by up-regulated transcripts common to all bacterial treatments at
both 6 and 24 h (Figures 2A,E).
Transcripts with shared and unique expression patterns
were found among the different experimental conditions at
each time point (Figures 2A–C,E–G). Different numbers of
DEGs shared by two or more treatments were also seen and
changed with increased bacteria exposure time. For instance,
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five upregulated genes are uniquely shared by BD and EC
at 6 h, but none at 24 h. Conversely, no upregulated genes
were exclusively shared by BD and RG at 6 h, though nine
genes specific to both groups are found at 24 h. Heatmaps
of DEGs common to all groups at 6 and 24 h are plotted in
Figures 2D,H, respectively.
FIGURE 3 | Differentially expressed canonical pathways in human islets by all treatments at 6 and 24 h. Heatmaps indicating activation z-scores for differentially
expressed canonical pathways; (A) Cellular Immune Response, (B) Cytokine Signaling, (C) Humeral Immune Response, (D) Pathogen Influenced Signaling,
(E) Cellular Stress and Injury, (F) Disease Specific Signaling, and (G) Ingenuity Toxicity List Pathways. The color key indicates the direction of changes: orange color
shows predicted overall activation of the pathway and blue color indicates predicted overall inhibition of the pathway. Only pathways with absolute z-score ≥ 2 or ≤
−2 and p-value ≤0.05 (in the IPA software) are shown. Pathways common to all treatments (underlined in green), pathways predominantly regulated by bacteria
(underlined in red), and pathways shared only by some treatments (underlined in blue) are illustrated.
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Canonical Pathways Modulated by
Bacteria and IL-1β in Human Islets
IPA is a web-based application for analysis and interpretation
of data derived from different omics experiments, such as RNA
Sequencing and microarrays. It provides a powerful tool to
uncover the significance of data and identify new targets or
candidate biomarkers within the context of biological systems.
IPA core analysis is an advanced platform that allows for
pathway analysis, networking data, upstream effect analysis,
disease relationships, and functional analysis. Lists of DEGs
by all groups were submitted separately to IPA software for
core analysis. After that, all groups were compared using
comparison analysis. Islet treatment with bacteria and IL-
1β revealed modulation of 83 canonical pathways [z-score
≥2 (for activation) and ≤ −2 (for inhibition) and p-value
≤0.05 in the IPA software] (Supplementary Table 4). From this
list, we focused on those pathways related to the following
categories of Ingenuity Canonical Pathways: Cellular Immune
Response, Cytokine Signaling, Pathogen Influenced Signaling,
Cellular stress and Injury, Disease Specific Signaling and Toxicity
List Pathways (Figure 3). At the set threshold, eight signaling
pathways were commonly activated by all treatments at both 6
and 24 h (underlined in green in Figure 3). These pathways are
Neuroinflammation, IL-1, HMGB1, Dendritic Cell Maturation,
TREM1, Role of IL-17F in Allergic Inflammatory Airway
Diseases, MIF-mediated Glucocorticoid Regulation, and Th17
Activation. On the other hand, Role of Pattern Recognition
Receptors in Recognition of Bacteria and Viruses, Th2 signaling,
and p38 MAPK signaling pathways are highly activated by
bacteria, but not by IL-1β. Noteworthy, there was a preferential
activation of specific canonical pathways by either BD, RG, or
EC at 6 h (Supplementary Table 4). BD specifically upregulated
tRNA Charging, while RG exclusively activated NGF Signaling
and SPINK1 General Cancer Pathway. EC revealed a preferential
remarkable activation of Interferon Signaling, IL-3 Signaling and
Leukocyte Extravasation Signaling. Such preferential pathway
activation by certain treatments reflects the unique ability of the
islets to respond to distinct bacterial stimuli. It is also noteworthy
that T1D Signaling and Role of RIG1-like Receptors in Antiviral
Innate Immunity are clearly upregulated at 6 h by EC, RG, and
IL-1β, but not by BD.
Antioxidant action of Vitamin C is the only pathway
inhibited/downregulated at 6 h by all treatments. Inhibition of
the nuclear receptor LXR/RXR activation was evident in all
groups with more pronounced inhibition by BD and IL-Iβ at 24 h
and RG at both 6 and 24 h.
Upstream Regulators, Diseases and Gene
Network Induced Bacteria, and IL-1β in
Human Islets
IPA core analysis including upstream effect, diseases, and
networks analyses were performed for all DEGs. The top
predicted upstream regulators, diseases, and in silico generated
networks are summarized in Table 1. Upstream effect analysis
is usually used to identify upstream factors that might drive the
expression of DEGs. Similarities were observed between bacteria
and IL-1β treated groups. Lipopolysaccharide (LPS) and TNF are
two upstream regulators shared by all groups at both 6 and 24 h.
In addition, IL-1β is common to all bacterial treatments at one
or both time points. It is noteworthy that the poly rI:rC-RNA, an
anti-viral response factor, was predicted to be uniquely activated
by BD at 6 h.
Regarding diseases and disorders associated with the datasets
of DEGs, inflammatory response and organismal injury and
abnormalities are shared by all treatments, though with different
numbers of focus molecules. For instance, the Islet Inflammatory
Response to EC was associated with activation of 248 and 160
molecules at 6 and 24 h, respectively. On the other hand, BD
Islet Inflammatory Response was associated with only 63 and
86 molecules at 6 and 24 h, respectively. RG treatment was
associated with 163 and 121 molecules at 6 and 24 h, respectively.
Such variation in number of genes associated with each bacteria
represents a scaling of the islet response toward the different
stimuli based on their unique molecular constituents.
DEGs Common to All Treatments and
Those Unique to Each Bacteria
Due to similarities in the activation of important canonical
pathways, upstream regulators and disease associations among
different bacterial exposures, we next focused on DEGs
commonly expressed by each treatment at the two studied
time points. This latter set of molecules could help uncover
the intrinsic islet responses against invading bacteria and/or
their products. First, we analyzed genes co-regulated at both 6
and 24 h by each treatment, then compared subsequent lists of
intersected genes.
From the lists of downregulated genes, BD, EC, RG, and
IL-1β downregulated the expression of 12, 39, 29, and 163
genes at both 6 and 24 h (Figure 4A, Supplementary Table 5).
Further intersection of these genes revealed five genes universally
downregulated by all bacteria, as well as, IL-1β. These genes are
mainly enzymes, kinases, and receptors (Figures 4C,D, Table 2,
and Supplementary Table 6) such as EPHA4, MS4A6A, PRSS2,
OXGR1, and PLCE1.
In a similar way, from the lists of upregulated genes,
BD, EC, RG, and IL-1β upregulated the expression of 62,
167, 122, and 334 genes at both 6 and 24 h (Figure 4B,
Supplementary Table 5). Further intersection of these genes
revealed 47 genes universally upregulated by all bacteria as well as
IL-1β. These 47 genes are categorized as follows: 42.6% cytokines,
14.9% enzymes, 10.6% receptors, 8.5% transcription regulators,
6.4% transporters, 2% kinases, and 14.9% others (Figures 4E,F,
Table 2, and Supplementary Table 6). Commonly upregulated
cytokines and chemokines include several interleukins e.g., IL-
1A, IL-1B, IL-6, IL-7, and IL-23A; members of C-C motif
chemokines e.g., CCL2, CCL3, CCL4, and CCL20; members of
C-X-C motif chemokines e.g., CXCL1, CXCL2, CXCL6, and IL-
8 and NAMPT. Upregulated enzymes are as follows: ZC3H12A,
SOD2, PTGS2, BIRC3, TNFAIP3, and PLA2G4C. Upregulated
receptors are FFAR2 (free fatty acid receptor 2), PTAFR, ICAM1,
IL17RB, and IL7R. Transcription regulators areCEBPD, NFKBIA,
and RELB. Upregulated transporters are SLC30A2, SLC6A14,
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TABLE 1 | Summary of top upstream regulators, diseases and disorders, and networks associated with exposure to bacteria or IL-1β at 6 and 24 h.
Experimental
condition
Top upstream regulators Top diseases and disorders Top networks
Name z-score p-value Name p-value No of focus
molecules
Name Score No of focus
molecules
BD-6 h vs. SFC LPS 8.4 4.27E-54 Cell death and survival 8.26E-32 51 Hematological disease, immunological disease,
organismal injury and abnormalities
30 17
TNF 7.4 7.2E-49 Inflammatory response 1.03E-31 63
poly
rI:rC-RNA
6.7 1.02E-47 Cellular movement, immune cell
trafficking
2.63E-29 58
BD-24 h vs. SFC IL1β 6.9 1.79E-48 Dermatological diseases and
conditions
5.51E-33–9.61E-09 57 Cell-mediated immune response, cellular
development, cellular function and
maintenance
25 15
LPS 7.4 3.59E-44 Organismal injury and abnormalities 5.51E-33–3.22E-08 148
TNF 7.7 1.23E-43 Inflammatory response 4.84E-31–3.28E-08 86
EC-6 h vs. SFC TNF 11.7 6.04E-101 Inflammatory response 7.83E-58–8E-14 248 Inflammatory disease, cellular growth and
proliferation, lymphoid tissue structure and
development
36 24
IL1β 9.9 1.63E-90 Organismal injury and abnormalities 7.83E-58–7.65E-14 438
LPS 11.3 2E-89 Cellular movement 2.77E-54–6.05E-14 202
EC-24 h vs. SFC IL1β 8.3 9.38E-66 inflammatory response 6.66E-41–1.8E-09 160 Cellular development, cellular growth and
proliferation, hematological system
development and function
35 22
TNF 9.6 1.06E-63 Organismal injury and abnormalities 3.03E-40–2.15E-09 300
LPS 8.8 1.04E-61 Dermatological diseases and
conditions
6.31E-40–2.12E-09 89
RG-6 h vs. SFC TNF 9.8 1.72E-71 Inflammatory response 1.35E-48–1.7E-11 163 Humoral immune response, protein synthesis,
cell-to-cell signaling and interaction
31 20
NFκB 8.7 1.33E-69 Organismal injury and abnormalities 2.77E-44–2.39E-11 292
LPS 10.4 2.27E-68 Hematological system development
and function
7.56E-44–2.55E-11 147
RG-24 h vs. SFC IL1β 8.1 1.55E-63 Inflammatory response 1.21E-41–5.64E-10 121 Cellular development, cellular growth and
proliferation, connective tissue development
and function
29 18
TNF 9.0 2.75E-58 Organismal injury and abnormalities 2.59E-36–6.11E-10 217
LPS 9.2 7.14E-56 Hematological system development
and function
9.1E-36–5.91E-10 113
IL1β-6 h vs. SFC IL1β 10.4 1.22E-97 Inflammatory response 1.64E-49–1.24E-13 331 Cell-to-cell signaling and interaction,
immunological disease, inflammatory disease
37 28
TNF 13 1.17E-87 Cellular movement 2.3E-49–1.25E-13 330
LPS 11.8 1.77E-80 Immune cell trafficking 4.55E-48–1.25E-13 222
IL1β-24 h vs. SFC IL1β 9.5 3.4E-79 Inflammatory response 8.05E-48–4.06E-11 312 Cell morphology, cellular development, cellular
growth and proliferation
37 27
TNF 10.7 2.4E-75 Organismal injury and abnormalities 1.5E-47–4.43E-11 737
NFκB 8.3 1.79E-66 Cellular movement 6.19E-43–3.75E-11 290
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FIGURE 4 | Shared differentially expressed genes (DEGs) specific to each tested bacterium after 6 and 24 h. (A) Venn diagrams indicating the overlap of
down-regulated genes at both 6 and 24 h in each group. (B) Venn diagrams indicating the overlap of up-regulated genes at both 6 and 24 h in each group.
(C) Intersection of down-regulated genes shared by each treatment. (D) Functional annotations of genes commonly down-regulated in all groups. (E) Intersection of
up-regulated genes shared by each treatment. (F) Functional annotations of genes commonly up-regulated in all groups.
and SLC7A11. IRAK2 (Interleukin 1 receptor associated kinase
2) is the only receptor kinase shared by all three bacteria
and IL-1β.
This analysis also revealed genes uniquely up- and
downregulated by each bacterium (Figures 4C,E). In this
regard, BD uniquely upregulated four genes (MTHFD2, ADM2,
ASNS, CHAC1) and downregulated three genes (SMAD9,
NXPH3, TGFB3). EC uniquely upregulated only one gene
(SLC7A5) and downregulated seven genes (SLCO2A1, FGL2,
GIMAP6, MIR143HG, CD300LB, HAVCR2, MSR1). Finally, RG
uniquely upregulated seven genes (ANO9, PLEKHG3, BBC3,
ATF3, RARRES3, PIM3, HAMP) and downregulated five genes
(LINC00473, TSIX, CSF1R, ELFN2, WNT16).
Next, we measured the protein expression of six factors
from the commonly upregulated genes using either western
blotting (islet lysates) or ELISAs (islet culture supernatants).
Lysates from one donor were immunoblotted using specific
antibodies against NAMPT, SOD2, and TRAF3-Interacting
Protein 2 (TRAF3IP2, also called ACT1). NAMPT and SOD2
are from the list of commonly upregulated factors (fold
change ≥ 2). TRAF3IP2 is an NF-κB activator commonly
upregulated by all treatments at a lower cut off (fold change
≥1.5). Additionally, protein concentrations of four cytokines,
within the list of commonly upregulated genes, namely
CCL20, CXCL1, CXCL6, and IL-8 were measured in islet
culture supernatant.
NAMPT mRNA fold changes, as indicated by RNA-Seq, were
3.2 (6 h BD), 2.9 (24 h BD), 5.3 (6 h EC), 4.6 (24 h EC), 4.6
(6 h RG), 3.8 (24 h RG), 9.7 (6 h IL-1β), and 8.6 (24 h IL-
1β). With the exception of 6 h BD, a similar increase, though
at lower magnitude, in NAMPT protein expression was noted
(Figures 5A,B). SOD2mRNA fold changes were 3.2 (6 h BD), 3.4
(24 h BD), 7.1 (6 h EC), 7.2 (24 h EC), 6.3 (6 h RG), 6.3 (24 h RG),
15 (6 h IL-1β), and 15.8 (24 h IL-1β). A corresponding increase
in all groups, though at lower magnitude than that observed for
RNA levels, in SOD2 protein expression was observed by western
blotting (Figures 5A,C). ACT1 mRNA fold changes were 1.6 (for
BD), 2.0 (6 h EC), 1.6 (24 h EC), 2.2 (6 h RG), 1.8 (24 h RG), 2.5
(6 h IL-1β), and 1.8 (24 h IL-1β). A corresponding increase, but
surprisingly at a higher magnitude, in ACT1 protein fold changes
was detected (Figures 5A,D).
The increase in the three aforementioned proteins was also
tested using biological replicates. Islets from another two donors
not used for RNA-Seq were initially treated with IL-1β and EC
for 24 h and subsequently further stressed with hyperglycemia.
At the end of exposure to bacteria or IL-1β, islets from IL-
1β, EC, and SFC were stimulated with 16mM glucose for 4 h.
As shown in Figures 6A–D, NAMPT protein expression was
increased ∼9 and 6 times in IL-1β and EC treated groups
relative to controls. Similarly, ACT1 protein expression was
increased by ∼6 and 5.5-fold by IL-1β and EC treatments,
respectively. Notably, SOD2 protein expression was similar
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TABLE 2 | Differentially expressed genes (DEGs) shared by all treatments at both 6 and 24 h.
Symbol BD-6 h BD-24 h EC-6 h EC-24 h RG-6 h RG-24 h IL1β-6 h IL1β-24 h
CYTOKINES/CHEMOKINES
IL6 6.1 5.6 17.5 13.3 11.6 8.4 60.7 46.7
CCL20 3.1 4.4 14.9 10.1 7.8 5.8 43.0 26.5
CXCL1 4.0 4.8 12.2 10.0 8.8 6.8 38.9 22.6
CXCL5 4.5 6.9 13.2 11.0 7.2 6.7 36.6 33.0
CSF2 6.2 7.7 14.4 5.8 10.9 7.4 35.2 4.4
CXCL8 5.8 6.6 14.0 12.3 11.1 9.2 33.7 20.1
IL7 4.8 3.1 10.7 6.5 11.1 6.3 30.6 13.6
CXCL3 3.5 4.2 9.5 6.2 7.1 4.7 29.7 12.4
CXCL2 3.7 4.2 8.3 7.5 8.2 5.8 28.6 13.4
CXCL6 2.5 4.1 7.3 8.9 5.2 5.2 20.4 29.7
IL1β 19.4 14.4 27.9 15.7 24.5 16.8 18.3 10.6
LIF 3.1 2.4 6.3 4.6 4.8 3.2 17.7 7.9
IL1A 4.5 3.6 12.6 6.0 6.4 3.9 15.1 5.4
NAMPT 3.2 2.9 5.3 4.6 4.6 3.8 9.7 8.6
IL23A 9.3 3.2 12.5 3.3 12.5 4.6 7.5 4.1
CSF1 2.4 2.0 4.4 2.9 3.8 2.9 7.1 4.3
TNFSF15 2.4 2.7 3.6 2.5 3.2 2.5 6.9 3.1
CCL2 2.2 2.1 3.5 2.2 3.0 2.0 4.6 3.0
CCL4 11.0 5.9 10.9 5.2 14.6 6.5 4.2 3.6
CCL3 15.4 12.9 17.6 10.2 20.5 14.6 4.2 4.9
ENZYMES
ZC3H12A 2.7 3.0 5.0 5.3 5.5 4.6 15.6 11.1
SOD2 3.2 3.4 7.1 7.2 6.3 6.3 15.0 15.8
PTGS2 2.9 3.1 5.5 6.1 4.5 6.5 9.2 11.6
BIRC3 3.0 2.8 4.8 3.8 5.2 3.7 8.9 4.6
TNFAIP3 3.8 3.2 5.3 3.7 5.1 4.1 5.8 2.9
PLA2G4C 2.7 2.7 3.6 2.8 3.1 3.1 3.3 2.2
PLCE1 −2.3 −2.9 −3.9 −3.6 −2.6 −2.5 −6.3 −6.9
MMP1 2.2 2.4 3.0 2.8 2.2 2.4 3.9 3.9
PRSS2 −3.0 −2.6 −4.3 −4.2 −2.7 −2.9 −4.3 −2.7
RECEPTORS
FFAR2 3.4 2.7 5.1 3.6 7.3 4.6 11.5 5.6
PTAFR 2.1 2.4 5.3 3.3 3.2 2.2 5.9 3.6
OXGR1 −2.4 −2.1 −2.9 −2.6 −2.9 −2.9 −5.2 −5.5
ICAM1 5.0 3.1 8.2 4.5 8.6 4.5 10.8 5.5
IL17RB 4.1 4.4 5.4 5.9 5.1 7.7 5.4 6.7
IL7R 3.0 2.2 5.9 3.2 4.5 2.2 5.3 4.3
KINASES
IRAK2 2.6 2.2 3.6 2.4 3.5 2.5 4.1 3.0
EPHA4 −2.3 −2.2 −2.7 −2.4 −2.8 −2.2 −2.7 −3.1
TRANSCRIPTIONAL REGULATORS
NFκBIA 4.6 3.4 6.5 4.5 7.0 4.9 10.6 6.2
CEBPD 2.4 2.2 3.9 3.8 4.2 3.2 8.1 6.5
NFκB2 6.1 3.1 7.1 3.3 7.3 3.7 7.3 3.6
RELB 4.9 2.8 5.3 2.9 5.6 3.3 4.5 2.4
TRANSPORTERS
SLC6A14 2.6 3.4 9.0 4.7 4.5 2.6 17.0 13.7
SLC30A2 2.8 3.4 3.3 4.6 4.6 7.0 6.3 8.9
SLC7A11 2.9 2.5 3.1 3.0 2.3 2.2 2.3 3.5
(Continued)
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TABLE 2 | Continued
Symbol BD-6 h BD-24 h EC-6 h EC-24 h RG-6 h RG-24 h IL1β-6 h IL1β-24 h
OTHERS
FGB 2.5 4.8 6.8 7.7 4.2 6.5 13.5 17.3
SNPH 2.5 2.8 4.9 6.2 6.2 7.0 12.1 9.9
SOCS1 3.3 2.6 6.7 5.3 5.4 3.7 11.9 11.3
TNFAIP2 2.4 2.1 4.5 2.6 3.7 2.1 6.5 2.7
NCCRP1 4.2 3.3 6.2 4.9 3.8 3.7 6.4 6.1
GRASP 2.2 2.1 2.8 2.5 2.9 3.1 3.0 3.1
NEAT1 2.1 2.1 2.1 2.4 2.5 2.5 3.0 3.0
MS4A6A −4.7 −5.4 −6.8 −8.6 −6.3 −4.9 −3.3 −3.4
The color key indicates the direction of changes: red and green colors depict the fold changes of significant up- and down-regulated genes, respectively. Factors selected for validation
of RNA-Seq data using western blotting or ELISA are highlighted in bold.
FIGURE 5 | Protein expression levels for NAMPT, SOD2, and ACT1 was increased after islet incubation with bacteria and IL-1β. (A) Representative immunoblots for
three upregulated factors of interest; NAMPT, SOD2, and ACT1 from islet lysate of donor seven. (B–D) Except for NAMPT at 6 h treatment with BD, the three factors
revealed an overall increase in their expression at all-time points, compared to control islets. Data are shown as averages of fold changes relative to controls ±
standard deviations and are representative of three independent experiments.
between EC and IL-1β as it increased by 6.5 and 6.3 by IL-1β and
EC, respectively.
ELISA measurements of islet supernatants for IL-8, CXCL-
6, CXCL-1, and CCL20 levels revealed time dependent increases
by most treatments. These factors are known to increase during
islet inflammation and diabetes (26, 27). Such increases were
most pronounced by IL-1β (Figures 7A–D). However, only
IL-8 was consistently increased by all bacteria at both 6 and
24 h (Figure 7A).
DISCUSSION
In the present study, human pancreatic islet responses to selected
bacteria overrepresented in the intestine of T1D subjects were
measured and compared in vitro. Ruminococcus gnavus (RG),
a Gram-positive bacterium and a pathobiont-like species (i.e.,
member of gut commensals that have the capacity to behave
as pathogens), showed a spike in relative abundance in T1D-
susceptible children concomitant with decreased diversity of
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FIGURE 6 | Increased protein expression levels for NAMPT, SOD2, and ACT1 in islets exposed to bacteria and IL-1β were maintained during subsequent
hyperglycemia. (A) Representative immunoblots for NAMPT, SOD2, and ACT1 from islet lysate of donors 3 and 4 challenged with 16mM glucose for 4 h following
initial incubation with IL-1β or EC for 24 h. (B–D) The three factors revealed an overall increase in their expression in both treatments relative to control islets. Data are
shown as averages of fold changes relative to controls ± standard deviations and are representative of three independent experiments.
gut microbiome (15) was investigated in our study. Bacteroides
dorei (BD), a Gram-negative bacterium significantly elevated
in children becoming autoantibody positive (seroconverters)
compared to controls (non-converters) prior to the appearance of
the first islet autoantibody (14), was also included in our analysis.
Escherichia coli (EC) is another Gram-negative bacterium but
its abundance is not affected by gut dysbiosis. Since the latter
bacterium is known to elicit a potent immunostimulatory effect,
indicated by the release of proinflamatory cytokines from human
mononuclear cells exposed to its LPS (20), EC was used to
assess islet responses associated with BD and RG. IL-1β, a potent
inflammatory cytokine associated with islet failure in both types
of human diabetes (28, 29), served as a positive control.
Our RNA-Seq analysis of human islets exposed to selected
gut bacteria revealed alterations in gene expression levels at
both 6 and 24 h, with dominance in a number of DEGs
by EC (459 and 310, respectively) followed by RG (305 and
225, respectively) and BD (157 and 151, respectively). It is
noteworthy that the number of DEGs shared by each bacteria
with IL-1β followed the same pattern. Although the reasons
for such variation are largely unknown, the distinct structural
features among bacteria probably account for these differences.
Variation in the immunogenicity of LPS between EC and BD was
recently reported (20). In line with our findings, higher levels
of nuclear factor kappa B (NF-κB) induced cytokines e.g., IL-1β
and IL-6 were observed in human mononuclear cells following
incubation with LPS from EC compared to BD. Surprisingly,
the increased production of the above mentioned cytokines by
EC was associated with lower rate of diabetes incidence (20).
Intraperitoneal (i.p.) injection of LPS from EC delayed the onset
of T1D in non-obese diabetic (NOD) mice, whereas BD LPS had
no effect (20). Moreover, splenocytes isolated from NOD mice
24 h following i.p. injection of EC LPS were less responsive to
further in vitro stimulation by bacterial endotoxins compared
to BD LPS (20). This suggests that continuous exposure to EC
LPS, but not BD LPS, contribute to prevention of autoimmunity
via increasing the host microbial tolerance. The distinct islet
antibacterial response to RG is likely due to cell wall constituents
such as peptidoglycans and lipoteichoic acid (30). Although the
mechanism is still unclear, peptidoglycans and lipoteichoic acid
are able to induce an inflammatory response comparable to
that induced by LPS via activation of host pattern recognition
receptors (31). This probably explains the shared features seen
between both gram positive (RG) and gram negative (BD, EC) in
the present study.
Unique BD-Mediated Effects on the Human
Islet Transcriptome
BD exposure led to unique changes in islet gene expression.
ADM2, ASNS, and CHAC1 were among the set of
genes preferentially upregulated by BD. ADM2 encodes
adrenomedullin 2, also called intermedin, a novel secreted
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FIGURE 7 | Changes in protein levels of selected cytokines in islets culture supernatant following incubation with bacteria and IL-1β. Selected cytokines included IL-8
(A), CXCL6 (B), CXCL1 (C), and CCL20 (D). Only IL-8 revealed significantly increased levels in all experimental treatments at both 6 and 24 h. Data are shown as
averages ± standard deviations (n ≥ 3 donors) and are representative of three independent experiments. *P < 0.05; ns, not significant.
peptide belonging to calcitonin family hormones (32), with
its expression being upregulated in different stress conditions
including endoplasmic reticulum (er) and oxidative stress
(33, 34). Interestingly, overexpression of ADM2 in mice
improved insulin sensitivity in adipocytes (35), suggesting
its role in metabolism. The upregulated expression of ASNS
by BD, which encodes asparagine synthetase, is known to
increase the production of asparagine (ASN). ASN contributes
to insulin secretion from pancreatic islets via accelerating
the rate of cytosolic NADPH generation (36), demonstrating
a metabolic role for ASNS. Interestingly, the released ASN
is also sensed by bacteria and modulates the expression of
nearly 17% of its genes increasing the rate of bacterial growth
(37). This suggests a role for ASN in mediating the symbiosis
between islets and bacteria. The exclusive activation of the tRNA
charging/loading pathway by BD exposure confirms its ability
to affect amino acid metabolism and protein synthesis. tRNA
charging/loading with amino acids is mediated by the enzyme
aminoacyl-tRNA synthetase that precedes mRNA translation
by ribosomes (38). CHAC1 encodes glutathione-specific
gamma-glutamylcyclotransferase 1 that plays an important role
in glutathione metabolism and is associated with glutathione
depletion in stressed human islets (39). Glutathione contributes
to balancing the redox status of the islets and its deficiency
predisposes to diabetes (40–42). Additionally, CHAC1 expression
leads to increased inflammation during bacterial infection (43).
CHAC1 inhibition reduced il-6, il-8, and CCL2 secretion in cells
stimulated with LPS or flagellin (43), suggesting a role forCHAC1
in mediating tissue inflammation through controlling the release
of cytokines. Its upregulation would clearly be proinflammatory,
create insulitis and alter islet redox state. Genes encoding
TGF-β3 and SMAD9 were downregulated by BD. TGF-β
signaling regulates development, differentiation, and function
of pancreatic β-cells (44, 45). TGF-β3 has been also suggested
to play both immunomodulatory and anti-inflammatory roles
(46, 47). Interestingly, SMAD9 downregulation was evident in
transcriptomic profiling of isolated pancreatic islets from T1D
patients (48). In conclusion, our results suggest that BD exposure
uniquely affects insulin secretion, islet metabolic functions and
islet cell differentiation while promoting inflammation.
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Unique RG-Mediated Effects on the Human
Islet Transcriptome
RG exposure also resulted in unique gene expression changes.
BBC3 (BCL2 binding component 3) and ATF3 (activating
transcription factor 3) are two genes exclusively induced by
RG in human islets. Both BBC3 and ATF3 were reported to
play important roles in stress-induced β-cell apoptosis (49–
51). Interestingly, ATF3 upregulation was also found to mediate
protection against Gram-positive bacteria by enhancing cytokine
production during bacterial infection (52). In addition to
that, HAMP (a gene coding for hepcidin) was listed among
genes with increased expression in RG-treated islets. Hepcidin
is well known for its role in iron metabolism (53). It has
a known connection to the antimicrobial response as its
concentrations are increased following exposure to bacteria
(54). HAMP acts to starve bacteria of iron. Given that
hepcidin expression in the pancreas is exclusive to insulin
granules of islet β-cells (55), our analysis points to hepcidin
as a critical antimicrobial peptide upregulated during insulin
secretion. Iron also regulates different aspects of islet β cell
functions including glucose stimulated insulin secretion (56).
Wnt signaling plays a role in immunomodulation (57). The
Wnt family member WNT16 is exclusively downregulated
in islets by RG. Interestingly, WNT16 is downregulated in
several autoimmune diseases including lupus and arthritis
(58). Although earlier reports suggested abundant expression
in the pancreas (59), the specific cells expressing WNT16 in
the pancreas remains undefined. Notably, glucocorticoids are
known for their immunosuppressive properties and a dose-
dependent inhibition of WNT16 was reported in mouse bone
tissues following glucocorticoid treatment (60). Interestingly,
overexpression ofWNT16 in mouse bone cells was able to revert
glucocorticoid-induced damage (60). Taken together, these data
point to WNT16 as an islet immunomodulator whose expression
is downregulated under stress conditions.
Bacteria-Specific Effects on the Human
Islet Transcriptome
BD, EC, and RG treated islets shared some features. From
the commonly upregulated list of cytokines/chemokines, three
factors revealed the highest increase in expression levels in
response to bacteria, especially RG, compared to IL-1β. These
factors are IL-23A, CCL3, and CCL4 (Table 2). A similar
induction of IL-23A, CCL3, and CCL4 by bacteria in other cell
types was reported (61–63), suggesting a major role for these
cytokines in antibacterial defense. The upregulated transcript
levels for IL-23A and CCL3 were found associated with high
incidence of autoimmunity (64). Conversely, the role of CCL4
during T1D appears to be protective (65).
Transcriptome Changes Shared by
All Treatments
Five genes were found to be commonly downregulated by all
bacteria and IL-1β exposure; OXGR1, PRSS2, MS4A6A, PLCE1,
and EPHA4. EPHA4 (EPH receptor A4) belongs to the protein-
tyrosine kinase family. Dysregulated EPH/ephrin signaling is
known to affect hormone secretion in human and mouse
islets (66, 67). Although the biological relevance of the other
downregulated genes, OXGR1, PRSS2, MS4A6A, PLCE1, to T1D
is unknown, these factors might also have important roles
in the pancreas. For instance, Oxgr1 knockout mice revealed
inflammatory changes in the middle ear with a significant degree
of hearing loss, suggesting a role for OXGR1 in counteracting
inflammation (68).
Our comparison analysis using IPA software revealed 47 genes
upregulated by all bacteria and IL-1β. IL-1β transcription is
strongly induced by all the bacteria providing a basis for these
commonalities. These set of genes is dominated by cytokines
(20/47), enzymes (7/47), and receptors (5/47). IL-1β expression
is known to activate NF-kB pathway (69, 70), the increased
expression of transcripts for RelB and NF-kB2 (P52) subunits of
NF-kB observed in our RNA-Seq is most likely induced by islet
overexpression of IL-1β. Such activation of the NF-kB pathway
can have beneficial effects on cells (71). However, persistent
release of NF-kB dependent factors, including inflammatory
cytokines (e.g., IL-8, CXCL6, CXCL1, and CCL20), adhesion
molecules (e.g., ICAM1), G protein coupled receptors (e.g.,
FFAR2 or GPR43), enzymes (e.g., PTGS2 and TRAFIP3, or A20),
and matrix metallopeptidases (e.g., MMP1), could have very
deleterious effects on islets (72–74). IL-1R signaling plays an
important role during both diabetes progression and rejection
of islet grafts during transplantation by modulating IL-1β action
(75, 76). IRAK2, an enzyme that regulates IL-1β action (77),
was also found to be increased in our RNA-Seq analysis by all
groups. Such IRAK2 upregulation is probably associated with
sustained auto-stimulatory effects of IL-1β on islet cells (71).
It is noteworthy that, activation of NF-kB pathway was also
accompanied with NF-kBIA (NF-kB inhibitor α) upregulation
that was probably due to its continuous nucleocytoplasmic
shuttling to counteract the islet damage induced by NF-kB (78).
The release of four chemokines, namely IL-8, CXCL6, CXCL1,
and CCL20, known to be regulated by NF-kB activation was
partly confirmed using ELISA.
Our RNA-Seq analysis surprisingly revealed increased
expression of both IL-7 and IL-7R by all treatments. IL-7 is a
cytokine known to be expressed by stromal cells in lymphoid
tissues and bone marrow (79), but has never been reported
in islets. The cellular source of these factors in human islets
requires investigation.
It is noteworthy that SLC6A14 (Solute Carrier Family 6
Member 14) which encodes an l-arginine transporter protein,
was upregulated by all treatments. Islet exposure to L-
arginine is known to increase insulin secretion (80) again
suggesting bacterial influences on islet function. Exposure of
airway epithelia to bacterial flagellin led to upregulation of
SLC6A14 expression and increased uptake of L-arginine by
the cells (81). Moreover, inhibition of SLC6A14-dependent L-
arginine transport enhances bacterial attachment, suggesting an
additional role for SLC6A14 in islets via inhibiting bacterial
pathogenesis (81).
Upregulated expression of intracellular NAMPT, TRAF3IP2,
and SOD2 was confirmed at the protein level using western
blotting (Figures 5, 6). NAMPT encodes nicotinamide
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phosphoribosyltransferase, a rate-limiting enzyme for NAD(+)
biosynthesis (82). NAMPT expression has been reported in
islet β-cells (83). Interestingly, NAMPT upregulation through
exogenous administration of nicotinamide mononucleotide
corrected islet damage induced by inflammatory cytokines IL-1β
and TNF-α (84), suggesting a protective role for NAMPT in
during islet stress. TRAF3IP2 is implicated in NF-kB activation
in many tissues during inflammation (85–87). SOD2 was
abundantly expressed in islets, as indicated by its signal intensity
in our immunoblots. Heterozygous deletion of SOD2 has been
shown to cause impaired insulin secretion in a mice model of
obesity (88).
Signaling Pathways Activated by Islets
Exposed to Bacteria
Our IPA core analysis confirmed the inflammatory nature of the
islet antibacterial response. In line with increased IL-1β mRNA
in our RNA-Seq DEGs, IL-1 signaling was found among the
top canonical pathways upregulated by all treatments. Another
upregulated pathway is the intracellular accumulation of nitric
oxide synthase (NOS) which is associated with mitochondrial
dysfunction and correlates with the severity of islet inflammation
(89). The inflammatory response pathway was the top disease
category altered by bacteria and cytokine treatment in our IPA
functional analysis. The comparatively limited inflammatory
response induced by BD complements our knowledge about
its weak immunostimulatory effects (20). TREM1 (triggering
receptor on myeloid cells 1) is the topmost activated canonical
pathway in our system. Upregulation of TREM1 signaling
pathway is associated with increased production of inflammatory
cytokines and possibly contributes to islet damage (90–92).
TREM1 upregulation was also noted to correlate with the severity
of bacterial infection via enhancing NF-κB pathway (93, 94).
The limitations of the present study should be acknowledged.
First, due to cost considerations, only eight human subjects were
tested. This might affect the reproducibility of data when larger
numbers of subjects are tested. Second, inclusion of commensal
gut species not associated with islet inflammation were not
evaluated. Thus, with the current design it is unclear whether
the reported responses were specific to the tested bacteria or
reflect a shared islet response to all bacteria. Third, other in
vivo factors contributing to complexity of islet response e.g.,
genetic susceptibility and signaling provided by islet juxtaposed
tissues are missing. Lastly, commercial bacterial strains from the
ATCC were used in this study. Recent reports have demonstrated
genomic variation and strain-specific functional adaptation of
gut bacteria in individuals with diseases (95, 96). Therefore,
bacteria isolated from diabetic individuals could induce a
different islet response.
In summary, our in vitro system uncovered key features of
the human islet response against invading gut bacteria and their
products (Figure 8). BD and RG uniquely influenced the human
islet transcriptome. These alterations would clearly affect islet
function and survival. Although direct role of bacteria in T1D
is under investigation, in the present study, proinflammatory
features such as cytokine and chemokine induction fit with the
FIGURE 8 | Schematic representation of human islet response against T1D-associated bacteria. Gut bacteria traverse the damaged gut barrier and reach the
pancreas. Upon reaching the pancreatic islets, bacteria elicit islet response via several pathways including activation of antimicrobial response factors, increased
production of cytokines and chemokines, activation of TREM1 signaling, increased oxidative stress levels and enhanced amino acid synthesis. The activated
pathways contribute to both islet damage and microbial survival which ultimately cause islet inflammation and increase the severity of autoimmunity.
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observation of infiltrating immune cells into islets in humanT1D.
Future mechanistic studies involving in vivo models are needed
to link these changes to T1D pathogenesis.
DATA AVAILABILITY STATEMENT
The datasets generated for this study can be found in GEO under
the accession number GSE131320, https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE131320. GEO Accession viewer
NCBI’s Gene Expression Omnibus (GEO) is a public archive and
resource for gene expression data.
AUTHOR CONTRIBUTIONS
AA andHJ: experimental design and execution, data analysis, and
manuscript preparation. RH and NS: experimental design, data
analysis, and reviewed the manuscript.
FUNDING
This work was supported by grants to NS from NIAID
(UO1AI130841, UO1AI102012), Leona M. and Harry B.
Helmsley Charitable Trust (2018PG-T1D048), the Juvenile
Diabetes Research Foundation (2-SRA-2016-288-S-B, 1-
PNF2014-165-A-V), and the J. W. Kieckhefer Foundation.
The University of Nebraska DNA Sequencing Core receives
partial support from the National Institute for General
Medical Science (NIGMS) INBRE–P20GM103427-14 and
COBRE−1P30GM110768-01 grants as well as The Fred &
Pamela Buffett Cancer Center Support Grant–P30CA036727.
This publication’s contents are the sole responsibility of the
authors and do not necessarily represent the official views of the
NIH or NIGMS. We also thank the Bioinformatics and Systems
Biology Core at UNMC for providing human islet RNA-Seq data
alignment and differential gene expression data (for subsequent
IPA analyses), which receives support from Nebraska Research
Initiative (NRI) and NIH (2P20GM103427 and 5P30CA036727).
ACKNOWLEDGMENTS
The authors would like to thank all members of Sarvetnick
lab for their helpful comments during the preparation of
this manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.02623/full#supplementary-material
REFERENCES
1. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, Group ES.
Incidence trends for childhood type 1 diabetes in Europe during 1989–2003
and predicted new cases 2005–20: amulticentre prospective registration study.
Lancet. (2009) 373:2027–33. doi: 10.1016/S0140-6736(09)60568-7
2. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA,
et al. Demonstration of islet-autoreactive CD8T cells in insulitic lesions
from recent onset and long-term type 1 diabetes patients. J Exp Med. (2012)
209:51–60. doi: 10.1084/jem.20111187
3. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler A-G. Brief
communication: early appearance of islet autoantibodies predicts childhood
type 1 diabetes in offspring of diabetic parents. Ann Int Med. (2004) 140:882–
6. doi: 10.7326/0003-4819-140-11-200406010-00009
4. Achenbach P, Bonifacio E, Koczwara K, Ziegler A-G. Natural history of type 1
diabetes. Diabetes. (2005) 54:S25–31. doi: 10.2337/diabetes.54.suppl_2.S25
5. Abdellatif AM, Sarvetnick NE. Current understanding of the role
of gut dysbiosis in type 1 diabetes. J Diabetes. (2019) 11:632–44.
doi: 10.1111/1753-0407.12915
6. Helander HF, Fändriks L. Surface area of the digestive tract–revisited. Scand J
Gastroenterol. (2014) 49:681–9. doi: 10.3109/00365521.2014.898326
7. Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E.
Immunologic activity in the small intestinal mucosa of pediatric patients with
type 1 diabetes. Diabetes. (2003) 52:2287–95. doi: 10.2337/diabetes.52.9.2287
8. Pellegrini S, Sordi V, Bolla AM, Saita D, Ferrarese R, Canducci F, et al.
Duodenal mucosa of patients with type 1 diabetes shows distinctive
inflammatory profile and microbiota. J Clin Endocrinol Metab. (2017)
102:1468–77. doi: 10.1210/jc.2016-3222
9. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB,Mukherjee
N, et al. Gut microbiome metagenomics analysis suggests a functional model
for the development of autoimmunity for type 1 diabetes. PLoS ONE. (2011)
6:e25792. doi: 10.1371/journal.pone.0025792
10. de Goffau MC, Fuentes S, van den Bogert B, Honkanen H, de Vos WM,
Welling GW, et al. Aberrant gut microbiota composition at the onset
of type 1 diabetes in young children. Diabetologia. (2014) 57:1569–77.
doi: 10.1007/s00125-014-3274-0
11. de Goffau MC, Luopajarvi K, Knip M, Ilonen J, Ruohtula T, Harkonen
T, et al. Fecal microbiota composition differs between children with
beta-cell autoimmunity and those without. Diabetes. (2013) 62:1238–44.
doi: 10.2337/db12-0526
12. Mejia-Leon ME, Petrosino JF, Ajami NJ, Dominguez-Bello MG, de la Barca
AM. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci
Rep. (2014) 4:3814. doi: 10.1038/srep03814
13. Pinto E, Anselmo M, Calha M, Bottrill A, Duarte I, Andrew PW, et al.
The intestinal proteome of diabetic and control children is enriched with
different microbial and host proteins. Microbiology. (2017) 163:161–74.
doi: 10.1099/mic.0.000412
14. Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT,
Kemppainen KM, et al. Bacteroides dorei dominates gut microbiome prior
to autoimmunity in Finnish children at high risk for type 1 diabetes. Front
Microbiol. (2014) 5:678. doi: 10.3389/fmicb.2014.00678
15. Kostic AD, Gevers D, Siljander H, Vatanen T, Hyotylainen T, Hamalainen AM,
et al. The dynamics of the human infant gut microbiome in development and
in progression toward type 1 diabetes. Cell Host Microbe. (2015) 17:260–73.
doi: 10.1016/j.chom.2015.01.001
16. Maffeis C, Martina A, Corradi M, Quarella S, Nori N, Torriani S,
et al. Association between intestinal permeability and faecal microbiota
composition in Italian children with beta cell autoimmunity at risk for
type 1 diabetes. Diabetes Metab Res Rev. (2016) 32:700–9. doi: 10.1002/dm
rr.2790
17. Korsgren S, Molin Y, Salmela K, Lundgren T, Melhus A, Korsgren O. On the
etiology of type 1 diabetes: a new animal model signifying a decisive role for
bacteria eliciting an adverse innate immunity response. Am J Pathol. (2012)
181:1735–48. doi: 10.1016/j.ajpath.2012.07.022
18. Costa FR, Francozo MC, de Oliveira GG, Ignacio A, Castoldi A, Zamboni
DS, et al. Gut microbiota translocation to the pancreatic lymph nodes triggers
NOD2 activation and contributes to T1D onset. J Exp Med. (2016) 213:1223–
39. doi: 10.1084/jem.20150744
Frontiers in Immunology | www.frontiersin.org 15 November 2019 | Volume 10 | Article 2623
Abdellatif et al. Human Islets Antibacterial Response
19. Stewart CJ, Ajami NJ, O’Brien JL, Hutchinson DS, Smith DP, Wong MC, et al.
Temporal development of the gut microbiome in early childhood from the
TEDDY study. Nature. (2018) 562:583–88. doi: 10.1038/s41586-018-0617-x
20. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA,
Yassour M, et al. Variation in microbiome LPS immunogenicity
contributes to autoimmunity in humans. Cell. (2016) 165:842–53.
doi: 10.1016/j.cell.2016.04.007
21. NIH CIT Consortium Chemistry Manufacturing Controls Monitoring
Committee, NIH CIT Consortium. Purified human pancreatic islet:
qualitative and quantitative assessment of islets using dithizone (DTZ):
standard operating procedure of the NIH clinical islet transplantation
consortium. CellR4 Repair Replace Regen Reprogram. (2015) 3:e1369.
22. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential
gene and transcript expression analysis of RNA-seq experiments with TopHat
and Cufflinks. Nat Protoc. (2012) 7:562–78. doi: 10.1038/nprot.2012.016
23. Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis
approaches in ingenuity pathway analysis. Bioinformatics. (2013) 30:523–30.
doi: 10.1093/bioinformatics/btt703
24. Peng X, Xie G, Wang Z, Lin H, Zhou T, Xiang P, et al. SKLB-163, a
new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by
affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. (2014) 5:e1143.
doi: 10.1038/cddis.2014.107
25. Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate
data using Principal Component Analysis and heatmap. Nucleic Acids Res.
(2015) 43:W566–70. doi: 10.1093/nar/gkv468
26. Cowley MJ, Weinberg A, Zammit NW, Walters SN, Hawthorne WJ,
Loudovaris T, et al. Human islets express a marked proinflammatory
molecular signature prior to transplantation. Cell Transplant. (2012) 21:2063–
78. doi: 10.3727/096368911X627372
27. Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid
decarboxylase-65 and anti-IA-2 autoantibodies are associated with different
immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin
Exp Immunol. (2012) 168:60–7. doi: 10.1111/j.1365-2249.2011.04538.x
28. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1β in
type 2 diabetes. Curr Opin Endocrinol Diabet Obes. (2010) 17:314–21.
doi: 10.1097/MED.0b013e32833bf6dc
29. Metcalfe KA, Hitman GA, Pociot F, Bergholdt R, Tuomilehto-Wolf
E, Tuomilehto J, et al. An association between type 1 diabetes and
the interleukin-1 receptor type 1 gene. Hum Immunol. (1996) 51:41–8.
doi: 10.1016/S0198-8859(96)00206-6
30. Desvaux M, Dumas E, Chafsey I, Hebraud M. Protein cell
surface display in Gram-positive bacteria: from single protein to
macromolecular protein structure. FEMS Microbiol Lett. (2006) 256:1–15.
doi: 10.1111/j.1574-6968.2006.00122.x
31. Wang JE, Dahle MK, McDonald M, Foster SJ, Aasen AO, Thiemermann
C. Peptidoglycan and lipoteichoic acid in gram-positive bacterial sepsis:
receptors, signal transduction, biological effects, and synergism. Shock. (2003)
20:402–14. doi: 10.1097/01.shk.0000092268.01859.0d
32. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a
calcitonin/calcitonin gene-related peptide family peptide acting through
the calcitonin receptor-like receptor/receptor activity-modifying protein
receptor complexes. J Biol Chem. (2004) 279:7264–74. doi: 10.1074/jbc.M3053
32200
33. Hagiwara M, Bledsoe G, Yang ZR, Smith RS Jr, Chao L, Chao J. Intermedin
ameliorates vascular and renal injury by inhibition of oxidative stress. Am J
Physiol Renal Physiol. (2008) 295:F1735–43. doi: 10.1152/ajprenal.90427.2008
34. Kovaleva IE, Garaeva AA, Chumakov PM, Evstafieva AG.
Intermedin/adrenomedullin 2 is a stress-inducible gene controlled
by activating transcription factor 4. Gene. (2016) 590:177–85.
doi: 10.1016/j.gene.2016.06.037
35. Zhang SY, Lv Y, Zhang H, Gao S, Wang T, Feng J, et al. Adrenomedullin
2 improves early obesity-induced adipose insulin resistance by
inhibiting the class II MHC in adipocytes. Diabetes. (2016) 65:2342–55.
doi: 10.2337/db15-1626
36. Malaisse-Lagae F, Welsh M, Lebrun P, Herchuelz A, Sener A, Hellerstrom C,
et al. The stimulus-secretion coupling of amino acid-induced insulin release.
Secretory Oxidative Response Pancreat Islets L-asparagine. Diabetes. (1984)
33:464–9. doi: 10.2337/diab.33.5.464
37. Baruch M, Belotserkovsky I, Hertzog BB, Ravins M, Dov E, McIver
KS, et al. An extracellular bacterial pathogen modulates host metabolism
to regulate its own sensing and proliferation. Cell. (2014) 156:97–108.
doi: 10.1016/j.cell.2014.01.035
38. Park SG, Schimmel P, Kim S. Aminoacyl tRNA synthetases and their
connections to disease. Proc Natl Acad Sci USA. (2008) 105:11043–9.
doi: 10.1073/pnas.0802862105
39. Bruni A, Pepper AR, Pawlick RL, Gala-Lopez B, Gamble AF, Kin T, et al.
Ferroptosis-inducing agents compromise in vitro human islet viability and
function. Cell Death Dis. (2018) 9:595. doi: 10.1038/s41419-018-0506-0
40. Harmon JS, Bogdani M, Parazzoli SD, Mak SS, Oseid EA, Berghmans M,
et al. Beta-cell-specific overexpression of glutathione peroxidase preserves
intranuclear MafA and reverses diabetes in db/db mice. Endocrinology. (2009)
150:4855–62. doi: 10.1210/en.2009-0708
41. Robertson RP, Harmon JS. Pancreatic islet beta-cell and oxidative stress:
the importance of glutathione peroxidase. FEBS Lett. (2007) 581:3743–8.
doi: 10.1016/j.febslet.2007.03.087
42. Wang X, Vatamaniuk MZ, Roneker CA, Pepper MP, Hu LG, Simmons RA,
et al. Knockouts of SOD1 and GPX1 exert different impacts on murine islet
function and pancreatic integrity. Antioxid Redox Signal. (2011) 14:391–401.
doi: 10.1089/ars.2010.3302
43. Perra L, Balloy V, Foussigniere T, Moissenet D, Petat H, Mungrue
IN, et al. CHAC1 is differentially expressed in normal and cystic
fibrosis bronchial epithelial cells and regulates the inflammatory response
induced by Pseudomonas aeruginosa. Front Immunol. (2018) 9:2823.
doi: 10.3389/fimmu.2018.02823
44. Dichmann DS, Miller CP, Jensen J, Scott Heller R, Serup P. Expression
and misexpression of members of the FGF and TGFβ families of growth
factors in the developing mouse pancreas. Dev Dyn. (2003) 226:663–74.
doi: 10.1002/dvdy.10270
45. Suzuki T, Dai P, Hatakeyama T, Harada Y, Tanaka H, Yoshimura N, et al.
TGF-β signaling regulates pancreatic β-Cell proliferation through control of
cell cycle regulator p27 expression. Acta Histochem Cytochem. (2013) 46:51–8.
doi: 10.1267/ahc.12035
46. Hall BE, Wankhade UD, Konkel JE, Cherukuri K, Nagineni CN, Flanders KC,
et al. TGF-β3 knock-in ameliorates inflammation due to TGF-β1 deficiency
while promoting glucose tolerance. J Biol Chem. (2013) M113:480764.
doi: 10.1074/jbc.M113.480764
47. Matejuk A, Dwyer J, Hopke C, Vandenbark AA, Offner H. Opposing
roles for TGF-β1 and TGF-β3 isoforms in experimental autoimmune
encephalomyelitis. Cytokine. (2004) 25:45–51. doi: 10.1016/j.cyto.2003.
09.007
48. Planas R, Carrillo J, Sanchez A, Ruiz de Villa M, Nunez F, Verdaguer J,
et al. Gene expression profiles for the human pancreas and purified islets in
type 1 diabetes: new findings at clinical onset and in long-standing diabetes.
Clini Exp Immunol. (2010) 159:23–44. doi: 10.1111/j.1365-2249.2009.
04053.x
49. Hartman MG, Lu D, Kim ML, Kociba GJ, Shukri T, Buteau J, et al. Role for
activating transcription factor 3 in stress-induced beta-cell apoptosis.Mol Cell
Biol. (2004) 24:5721–32. doi: 10.1128/MCB.24.13.5721-5732.2004
50. Omori K, Mitsuhashi M, Ishiyama K, Nair I, Rawson J, Todorov I, et al.
mRNA of the pro-apoptotic gene BBC3 serves as a molecular marker for
TNF-alpha-induced islet damage in humans.Diabetologia. (2011) 54:2056–66.
doi: 10.1007/s00125-011-2183-8
51. Zmuda EJ, Viapiano M, Grey ST, Hadley G, Garcia-Ocana A, Hai T.
Deficiency of Atf3, an adaptive-response gene, protects islets and ameliorates
inflammation in a syngeneic mouse transplantation model. Diabetologia.
(2010) 53:1438–50. doi: 10.1007/s00125-010-1696-x
52. Nguyen CT, Kim EH, Luong TT, Pyo S, Rhee DK. TLR4 mediates
pneumolysin-induced ATF3 expression through the JNK/p38 pathway in
Streptococcus pneumoniae-infected RAW 264.7 cells.Mol Cells. (2015) 38:58–
64. doi: 10.14348/molcells.2015.2231
53. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta.
(2012) 1823:1434–43. doi: 10.1016/j.bbamcr.2012.01.014
54. Cuesta A, Meseguer J, Esteban MA. The antimicrobial peptide hepcidin
exerts an important role in the innate immunity against bacteria in
the bony fish gilthead seabream. Mol Immunol. (2008) 45:2333–42.
doi: 10.1016/j.molimm.2007.11.007
Frontiers in Immunology | www.frontiersin.org 16 November 2019 | Volume 10 | Article 2623
Abdellatif et al. Human Islets Antibacterial Response
55. Kulaksiz H, Fein E, Redecker P, Stremmel W, Adler G, Cetin Y. Pancreatic
beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol.
(2008) 197:241–9. doi: 10.1677/JOE-07-0528
56. Wang X, Fang X, Wang F. Pleiotropic actions of iron balance
in diabetes mellitus. Rev Endocr Metab Disord. (2015) 16:15–23.
doi: 10.1007/s11154-014-9303-y
57. Chae WJ, Bothwell ALM. Canonical and non-canonical wnt
signaling in immune cells. Trends Immunol. (2018) 39:830–47.
doi: 10.1016/j.it.2018.08.006
58. Swafford D, Manicassamy S. Wnt signaling in dendritic cells: its role in
regulation of immunity and tolerance. Discov Med. (2015) 19:303.
59. Fear MW, Kelsell DP, Spurr NK, Barnes MR. Wnt-16a, a novel Wnt-16
isoform, which shows differential expression in adult human tissues. Biochem
Biophys Res Commun. (2000) 278:814–20. doi: 10.1006/bbrc.2000.3852
60. Hildebrandt S, Baschant U, Thiele S, Tuckermann J, Hofbauer LC, Rauner M.
Glucocorticoids suppressWnt16 expression in osteoblasts in vitro and in vivo.
Sci Rep. (2018) 8:8711. doi: 10.1038/s41598-018-26300-z
61. Godinez I, Raffatellu M, Chu H, Paixao TA, Haneda T, Santos RL,
et al. Interleukin-23 orchestrates mucosal responses to Salmonella enterica
serotype Typhimurium in the intestine. Infect Immun. (2009) 77:387–98.
doi: 10.1128/IAI.00933-08
62. Sipert CR, Morandini AC, Dionisio TJ, Machado MA, Oliveira SH,
Campanelli AP, et al. In vitro regulation of CCL3 and CXCL12 by bacterial
by-products is dependent on site of origin of human oral fibroblasts. J Endod.
(2014) 40:95–100. doi: 10.1016/j.joen.2013.09.031
63. Yung SC, Murphy PM. Antimicrobial chemokines. Front Immunol. (2012)
3:276. doi: 10.3389/fimmu.2012.00276
64. Mastracci TL, Turatsinze JV, Book BK, Restrepo IA, Pugia MJ, Wiebke EA,
et al. Distinct gene expression pathways in islets from individuals with short-
and long-duration type 1 diabetes. Diabetes Obes Metab. (2018) 20:1859–67.
doi: 10.1111/dom.13298
65. Meagher C, Beilke J, Arreaza G, Mi QS, Chen W, Salojin K, et al.
Neutralization of interleukin-16 protects nonobese diabetic mice from
autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes.
(2010) 59:2862–71. doi: 10.2337/db09-0131
66. Hutchens T, Piston DW. EphA4 receptor forward signaling inhibits glucagon
secretion from α-cells. Diabetes. (2015) 64:3839–51. doi: 10.2337/db15-0488
67. Konstantinova I, Nikolova G, Ohara-Imaizumi M, Meda P, Kucera
T, Zarbalis K, et al. EphA-Ephrin-A-mediated β cell communication
regulates insulin secretion from pancreatic islets. Cell. (2007) 129:359–70.
doi: 10.1016/j.cell.2007.02.044
68. Kerschner JE, Hong W, Taylor SR, Kerschner JA, Khampang P, Wrege KC,
et al. A novel model of spontaneous otitis media with effusion (OME) in
the Oxgr1 knock-out mouse. Int J Pediatr Otorhinolaryngol. (2013) 77:79–84.
doi: 10.1016/j.ijporl.2012.09.037
69. Burke SJ, Stadler K, Lu D, Gleason E, Han A, Donohoe DR, et al. IL-1beta
reciprocally regulates chemokine and insulin secretion in pancreatic beta-
cells via NF-kappaB. Am J Physiol Endocrinol Metab. (2015) 309:E715–26.
doi: 10.1152/ajpendo.00153.2015
70. Ortis F, Miani M, Colli ML, Cunha DA, Gurzov EN, Allagnat F,
et al. Differential usage of NF-kappaB activating signals by IL-1beta
and TNF-alpha in pancreatic beta cells. FEBS Lett. (2012) 586:984–9.
doi: 10.1016/j.febslet.2012.02.021
71. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA.
Cytokine production by islets in health and diabetes: cellular origin,
regulation and function. Trends Endocrinol Metab. (2010) 21:261–7.
doi: 10.1016/j.tem.2009.12.010
72. Hammar E, Parnaud G, Bosco D, Perriraz N, Maedler K, Donath M, et al.
Extracellular matrix protects pancreatic beta-cells against apoptosis: role
of short- and long-term signaling pathways. Diabetes. (2004) 53:2034–41.
doi: 10.2337/diabetes.53.8.2034
73. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold
Spring Harb Perspect Biol. (2009) 1:a001651. doi: 10.1101/cshperspect.a001651
74. Shi G, Sun C, Gu W, Yang M, Zhang X, Zhai N, et al. Free fatty acid receptor
2, a candidate target for type 1 diabetes, induces cell apoptosis through ERK
signaling. J Mol Endocrinol. (2014) 53:367–80. doi: 10.1530/JME-14-0065
75. Jafarian-Tehrani M, Amrani A, Homo-Delarche F, Marquette C, DardenneM,
Haour F. Localization and characterization of interleukin-1 receptors in the
islets of Langerhans from control and nonobese diabetic mice. Endocrinology.
(1995) 136:609–13. doi: 10.1210/endo.136.2.7835294
76. Westwell-Roper C, Dai DL, Soukhatcheva G, Potter KJ, van Rooijen
N, Ehses JA, et al. IL-1 blockade attenuates islet amyloid polypeptide-
induced proinflammatory cytokine release and pancreatic islet graft
dysfunction. J Immunol. (2011) 187:2755–65. doi: 10.4049/jimmunol.
1002854
77. Meylan E, Tschopp J. IRAK2 takes its place in TLR signaling. Nat Immunol.
(2008) 9:581–2. doi: 10.1038/ni0608-581
78. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE,
et al. Oscillations in NF-kappaB signaling control the dynamics of gene
expression. Science. (2004) 306:704–8. doi: 10.1126/science.1099962
79. Fry TJ,Mackall CL. Interleukin-7: from bench to clinic. Blood. (2002) 99:3892–
904. doi: 10.1182/blood.V99.11.3892
80. Leiss V, Flockerzie K, Novakovic A, Rath M, Schonsiegel A, Birnbaumer L,
et al. Insulin secretion stimulated by L-arginine and its metabolite L-ornithine
depends on Galpha(i2). Am J Physiol Endocrinol Metab. (2014) 307:E800–12.
doi: 10.1152/ajpendo.00337.2014
81. Di Paola M, Park AJ, Ahmadi S, Roach EJ, Wu YS, Struder-Kypke M, et al.
SLC6A14 is a genetic modifier of cystic fibrosis that regulates Pseudomonas
aeruginosa attachment to human bronchial epithelial cells. MBio. (2017)
8:e02073-17. doi: 10.1128/mBio.02073-17
82. Garten A, Schuster S, Penke M, Gorski T, de Giorgis T, Kiess W. Physiological
and pathophysiological roles of NAMPT and NAD metabolism. Nat Rev
Endocrinol. (2015) 11:535–46. doi: 10.1038/nrendo.2015.117
83. Kover K, Tong PY, Watkins D, Clements M, Stehno-Bittel L, Novikova L,
et al. Expression and regulation of nampt in human islets. PLoS ONE. (2013)
8:e58767. doi: 10.1371/journal.pone.0058767
84. Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Nicotinamide
mononucleotide protects against pro-inflammatory cytokine-mediated
impairment of mouse islet function. Diabetologia. (2011) 54:3083–92.
doi: 10.1007/s00125-011-2288-0
85. Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, et al.
Act1, an NF-kappa B-activating protein. Proc Natl Acad Sci USA. (2000)
97:10489–93. doi: 10.1073/pnas.160265197
86. Sonder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist
U. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic
significance and signaling mechanisms. J Biol Chem. (2011) 286:12881–90.
doi: 10.1074/jbc.M110.199547
87. Venkatesan B, Valente AJ, Das NA, Carpenter AJ, Yoshida T, Delafontaine JL,
et al. CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial
dysfunction. Cell Signal. (2013) 25:359–71. doi: 10.1016/j.cellsig.2012.
10.009
88. Kang L, Dai C, Lustig ME, Bonner JS, Mayes WH, Mokshagundam S, et al.
Heterozygous SOD2 deletion impairs glucose-stimulated insulin secretion,
but not insulin action, in high-fat-fed mice. Diabetes. (2014) 63:3699–710.
doi: 10.2337/db13-1845
89. Zhong L, Tran T, Baguley TD, Lee SJ, Henke A, To A, et al. A novel
inhibitor of inducible NOS dimerization protects against cytokine-induced
rat beta cell dysfunction. Br J Pharmacol. (2018) 175:3470–85. doi: 10.1111/bp
h.14388
90. Thorsen SU, Pipper CB, Mortensen HB, Skogstrand K, Pociot F, Johannesen
J, et al. Levels of soluble TREM-1 in children with newly diagnosed
type 1 diabetes and their siblings without type 1 diabetes: a Danish
case-control study. Pediatr Diabetes. (2017) 18:749–54. doi: 10.1111/ped
i.12464
91. Wang X, Jia S, Geoffrey R, Alemzadeh R, Ghosh S, Hessner MJ.
Identification of a molecular signature in human type 1 diabetes mellitus
using serum and functional genomics. J Immunol. (2008) 180:1929–37.
doi: 10.4049/jimmunol.180.3.1929
92. Yuan Z, Syed MA, Panchal D, Joo M, Colonna M, Brantly M, et al.
Triggering receptor expressed on myeloid cells 1 (TREM-1)-mediated Bcl-2
induction prolongs macrophage survival. J Biol Chem. (2014) 289:15118–29.
doi: 10.1074/jbc.M113.536490
93. Liu F, Zhang X, Zhang B, Mao W, Liu T, Sun M, et al. TREM1: a
positive regulator for inflammatory response via NF-kappaB pathway in A549
cells infected with Mycoplasma pneumoniae. Biomed Pharmacother. (2018)
107:1466–72. doi: 10.1016/j.biopha.2018.07.176
Frontiers in Immunology | www.frontiersin.org 17 November 2019 | Volume 10 | Article 2623
Abdellatif et al. Human Islets Antibacterial Response
94. Sierra-Diaz E, Bravo Cuellar A, Ortiz Lazareno PC, Garcia Gutierrez
M, Georgina HF, Anaya Prado R. Urine TREM-1 as a marker of
urinary tract infection in children. J Int Med Res. (2017) 45:631–8.
doi: 10.1177/0300060517696199
95. Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, et al.
Extensive unexplored human microbiome diversity revealed by over 150,000
genomes from metagenomes spanning age, geography, and lifestyle. Cell.
(2019) 176:649–62. doi: 10.1016/j.cell.2019.01.001
96. Vatanen T, Plichta DR, Somani J, Münch PC, Arthur TD, Hall AB,
et al. Genomic variation and strain-specific functional adaptation in the
human gut microbiome during early life. Nat Microbiol. (2019) 4:470–9.
doi: 10.1038/s41564-018-0321-5
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Abdellatif, Jensen Smith, Harms and Sarvetnick. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Immunology | www.frontiersin.org 18 November 2019 | Volume 10 | Article 2623
